Latest News

In year 2 of SELECT-GCA, 6.0% of patients continuing upadacitinib flared vs 55.9% switched to placebo.

In phase 1 COMPARE, 4 of 6 patients with refractory RA achieved remission by week 36 following CD19 CAR T-cell therapy.

ACR 2026 data show 56.7% of patients with PsA met GLP-1 RA eligibility criteria, but only 15.7% were prescribed treatment.

Once-weekly retatrutide reduced WOMAC pain and body weight vs placebo in two phase 3 trials, with up to 69.6% of participants halving knee pain at week 68.

Two ACR Convergence 2026 studies tie GLP-1 receptor agonists to lower cardiovascular and mortality risk.

Two ACR 2026 abstracts report rising cardiovascular deaths in Sjögren syndrome and superior ESSDAI response with baricitinib vs hydroxychloroquine.

Kate Harnden, MBChB, PhD, discusses models predicting persistent arthritis after checkpoint inhibitor therapy, presented at EULAR 2026 and as an ACR plenary.

Jack Arnold and Rihards Buss preview 6 ACR 2026 abstracts spanning ICI arthritis, PsA proteomics, JAK inhibitor prescribing, and B-cell depletion.

The FDA approved tildrakizumab for adults with active psoriatic arthritis based on two phase 3 trials showing improved ACR20 response at week 24 vs placebo.

Jessica Gordon, MD, MS, and New York rheumatologists discuss who to screen for ILD, how to monitor without overimaging, and when to add antifibrotics.

Koji Ishikawa, MD, PhD, emphasized that 12 months of romosozumab showed benefits for osteoporosis.

The new 30-mg/5-mL formulation offers an alternative for adults who have difficulty swallowing capsules.

On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.

At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.

Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.

Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.

The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.

Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.

Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.

Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.

Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for PsA.

Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.

The designation follows phase 2 IMPACT trial data showing reduced adverse pregnancy outcomes in high-risk antiphospholipid syndrome.